Losartan Potassium Tablet, Film Coated
Product Images NDC 68788-7665

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-7665). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium Tablet Usp 50mg (Losartan25mg90s)

Label for Losartan Potassium 50 mg film-coated tablets, generic for Cozaar. The label shows dosage form, strength, manufacturer (Camber Pharmaceuticals, Inc., Piscataway, NJ), storage instructions, and warnings. The label includes directions for use in English and Spanish, a barcode, and caution against drug transfer, along with placeholder fields for lot number, expiration date, and product number.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over a 60-month study period for Losartan Potassium and Atenolol. The graph shows adjusted risk reduction of 13% with Losartan Potassium, with a p-value of 0.021, indicating statistical significance.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period between Atenolol and Losartan Potassium. Atenolol is represented by a dotted line and Losartan Potassium by a solid line, showing a lower stroke incidence for Losartan Potassium. The graph notes an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A clinical trial figure showing primary endpoint event rates and hazard ratios for Losartan Potassium versus Atenolol within demographic subgroups. It compares primary composite and stroke (fatal/non-fatal) outcomes across age, gender, race, isolated systolic hypertension (ISH), diabetes, and cardiovascular disease history, depicting event rates and confidence intervals in hazard ratio plots.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph depicting the percentage of patients experiencing an event over months, comparing Losartan Potassium and placebo groups. The graph shows risk reduction of 16.1% with a p-value of 0.022, illustrating a lower event rate in the Losartan Potassium group over a 48-month period.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium, showing its molecular arrangement including rings, functional groups, and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.